Tafenoquine interim data presentation scheduled
60 Degrees Pharmaceuticals plans to present interim data on tafenoquine for severe babesiosis. The event is scheduled for October 6, 2026, and marks a key regulatory milestone for …
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
60 Degrees Pharmaceuticals plans to present interim data on tafenoquine for severe babesiosis. The event is scheduled for October 6, 2026, and marks a key regulatory milestone for …
The company amended its warrant agency agreement effective October 1, 2026, to reflect conforming changes to the tradeable warrant form, confirming VStock Transfer, LLC as the pred…
The Federal Reserve Board approved an application by Isabella Bank Corporation.
Onfolio Holdings has filed an amended and restated bylaw document with the SEC, effective September 29, 2026.
NOVAGOLD RESOURCES INC filed Exhibit 10.1, a restated exploration and lode mining lease effective May 1, 1995, with Calista Corporation, to reflect all assignments through Feb. 11,…
The company announced dosing of healthy volunteers in its ANCHOR trial for KRRO-121, a potential treatment for urea cycle disorders, with patient dosing expected to begin in 2027.
NeoGenomics amended its bylaws to allow electing up to 11 directors and altering their number by one per year, contingent on shareholder approval.
Endovia and Lupvindol announced the FDA has granted CannEpil minor-use status for bone cancer pain in dogs, allowing it to pursue conditional approval and targeting a 2027 commerci…
The Nasdaq Hearings Panel granted SCWorx Corp.'s request to continue listing, citing regained compliance with Nasdaq's minimum bid price and public share requirements following a p…
The FDA released a request for information regarding early-phase ibogaine clinical trial designs and seeks public input on potential approaches.
ESS Tech, Inc. (ESS) confirmed that its common stock transitioned to the OTC market under the ticker GWHT following a NYSE suspension and determined to commence delisting. The comp…
Leidos Holdings filed an amended LLC agreement for a constrained business, omitting material schedules and exhibits.
The FDA has requested additional data, including OPMD natural history study results, but confirmed the pivotal trial remains on track to begin enrolling patients in mid-2027.
TELA Bio received FDA clearance for its Liora Monofilament Scaffold, expanding its product portfolio for soft tissue reconstruction. This marks the first full resorbable synthetic …
Vaxcyte reported positive top-line data from the OPUS-1 Phase 3 trial of its 31-valent pneumococcal conjugate vaccine candidate, VAX-31. The result demonstrates its ability to prov…
Quality Industrial Corp. has amended its Articles of Incorporation following the issuance of stock, receiving 51.9% shareholder approval. This regulatory update signifies the firm'…
Federal Reserve Board approves Fleur Capital Corporation's application, signaling regulatory support for the firm.
The Federal Reserve has extended the public comment period for its Regulation O modernization proposal until November 4, 2015.
Dragonfly Energy secured a waiver for its Liquidity covenant until September 30, 2026, for the fiscal month ending that date. This regulatory update is a 'Non-Material Event' under…
Leef Brands Inc. filed an 8-K to confirm the exclusion of the required audit report and management report on internal control. The omission of an independent auditor's report for t…